International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 3 , Pages 821-827, 1 November 2010

Concurrent Chemoradiotherapy With Paclitaxel and Nedaplatin Followed by Consolidation Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix: Preliminary Results of a Phase II Study

  • Mei-Qin Zhang, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Mei-Qin Zhang, M.D., Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-an Road, Shanghai 200032, P.R. China. Tel: (86) 21-64175590, ext. 2905; Fax: (86) 21-64174774
  • ,
  • Su-Ping Liu, M.D.
  • ,
  • Xiang-E. Wang, M.B.

Department of Gynecologic Oncology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China

Received 18 March 2009; received in revised form 31 August 2009; accepted 31 August 2009. published online 08 March 2010.

Purpose

To evaluate the efficacy and toxicities of concurrent chemoradiotherapy (CCRT) and consolidation chemotherapy in patients with locally advanced squamous cell cervical carcinoma.

Methods and Materials

Patients with LASCC (FIGO Stage IIB–IIIB) were treated with pelvic external beam radiotherapy (45 Gy for Stage IIB and 50 Gy for Stage III) and high-dose-rate intracavitary brachytherapy (50 Gy for Stage IIB and 35 Gy for Stage III). The cumulative dose at point A was 50 Gy for Stage IIB and 65 Gy for Stage III. Concurrent chemotherapy with paclitaxel (35 mg/m2) and nedaplatin (20 mg/m2) was given every week for 6 weeks. Consolidation chemotherapy with paclitaxel (135 mg/m2) and nedaplatin (60 mg/m2) was administered every 3 weeks for 4 cycles.

Results

All patients completed CCRT, and 28 of 34 patients completed consolidation chemotherapy. The complete response rate was 88% (95% CI, 73–96%). The most common Grade 3 or higher toxicities were leukopenia/neutropenia (10.9% of the cycles). During a median follow up of 23 months (range, 14–30 months), 5 patients had locoregional failure and 1 patient had distant metastasis. The estimated 2-year progression-free survival and overall survival were 82% (95% CI, 68–95%) and 93% (95% CI, 83–100%), respectively. Grade 3 late complications occurred in 3 patients (9%).

Conclusions

CCRT with paclitaxel and nedaplatin followed by consolidation chemotherapy is well tolerated and effective in patients with locally advanced squamous cell cervical carcinoma. Further randomized trials of comparing this regimen with the standard treatment are worth while.

Paclitaxel, Nedaplatin, Cervical carcinoma, Concurrent chemoradiotherapy, Consolidation chemotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Shanghai Municipality Bureau of Health Grant 034092 (to Mei-Qin Zhang).

 Conflict of interest: none.

PII: S0360-3016(09)03043-0

doi:10.1016/j.ijrobp.2009.08.069

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 3 , Pages 821-827, 1 November 2010